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Cystic fibrosis (CF; MIM# 219700) is the most frequent recessive disease in Caucasian patients. However, immigration from the Middle East
and Africa to Europe is revealing different CFTR mutations.
Here, we have described an 875+1G→A mutation, found for the first time in a homozygous state in an 8 yr old boy. He was the child of a
couple of Egyptian first level cousins, both carriers of the mutation.
The functional test revealed the 875+1G→A to be a severe mutation, leading to defective protein function as detected by nasal potential
difference (NPD) measurements.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Arab mutations; CFTR; Cystic fibrosis; 875+1G→A1. Introduction
Cystic fibrosis (CF; MIM# 219700) is the most common
recessive autosomal Caucasian disorder, carriers being 1:25 and
with an incidence of 1:2500–1:4400 in different populations
decreasing from north-west to south-eastern Europe [1,2].
First cloned in 1989, cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene (or ABCC7) (MIM 602421),
located on chromosome 7q31.2 encodes for a transmembrane
ATP-binding cassette protein, which principally functions as an
ion channel, regulating chloride ion traffic at the apical
membrane of epithelial cells [3].
More than 1600 CFTR mutations are currently reported and
listed in the CFTR mutation database [4]. Recently, in our
country an increasing number of newborns from immigrant⁎ Corresponding author. Cystic Fibrosis Regional Support Centre, Department of
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screening programmes for cystic fibrosis, available for 80% of
the whole neonatal population. Here, we would like to add to
the spectrum of CFTR mutations describing clinical, genetic
and functional data of an Egyptian CF patient with a rare
homozygous genotype.2. Case report
GG, male, 8 yrs old, is the last of five siblings, born in Italy in
2000 from a couple of Egyptian first cousins. One sister,
reported to be affected by cystic fibrosis, died at 2 months. A
first cousin is affected and alive ( Fig. 1). Newborn screening
was positive, with persistent hypertrypsinogenemia (127 ng/ml;
80 ng/ml at recall), while sweat chloride values in the first
months of life were not considered completely diagnostic
(sweat chloride: 54.64 and 57.30 mmol/l). First level mutation
screening was negative for delF508 and other 31 mutations [5],
then the infant was referred to the Regional CF Centre tod by Elsevier B.V. All rights reserved.
Fig. 1. The patient's family tree.
Fig. 2. NPD measurements. The agents indicated at the bottom were added at the
times (seconds) shown on the x axis. On the y axis, PD are expressed in mV. The
graph was obtained during measurements of the left nostril and is representative
of both nostrils.
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borderline sweat test. Due to linguistic and logistic difficulties
and to their different cultural backgrounds, the parents under-
estimated the importance of the diagnostic assessment, so the
patient was lost to follow-up.
In April 2004, he was sent to the CF Support Centre at the
Paediatric Department of Brescia (third level hospital) from a
peripheral hospital. In the first four years of life, he was often
hospitalized (more than 2 per year) for wheezing, recurrent
bronchopneumonia, chronic cough, and failure to thrive.
A repeated sweat test was performed and CF diagnosis was
confirmed (mean NaCl value: 95 mmol/l; cut-off value:
50 mmol/L). Pancreatic status was sufficient (faecal elastase
values N500 µg/g; faecal fat assessment b3%).
The child was taken in charge by our CF clinic, daily chest
physiotherapy started together with antibiotic therapy when
needed, salt and vitamin supplementation. There was no further
hospitalization after diagnosis and proper management of the
disease was started. Clinical symptoms were limited to upper
respiratory tract infections. Latest chest X-ray and CT thoracic
scan (2008) showed no pleuro-parenchymal lesions, no
bronchiectasies, and no hyperinflation. Ultra sound abdominal
examination (2008) showed no hepatic or pancreatic lesion. No
nasal polyposis was detected with rhinofibroscopy. No infection
by Staphylococcus aureus or Pseudomonas aeruginosa was
ever detected. Growth is on the 75th percentile for height and
weight.
3. CFTR sequencing and functional analysis
Extensive molecular analysis was performed using: (i)
screening for frequent mutations using different commercial
assays for CFTR gene; (ii) scanning of the 27 exons and their
boundaries using denaturing high pressure liquid phase
chromatography (DHPLC) [6]; (iii) screening for large CFTR
rearrangements using a MLPA assay which enabled detection of
20% of the rearrangements of previously unidentified alleles in
CF patients [7].Analysis identified the 875+1G→A mutation on both
chromosomes with no other alterations. Parents were tested
and found to be both healthy carriers for 875+1G→A.
The mutation leads to a single nucleotide substitution
(G→A) in the first nucleotide of intron 6a of CFTR gene.
The consequence is an mRNA splicing defect, as described in
1994 by Duarte et al. who first reported the mutation [4]. No
homozygote case has ever been described and this is the first
report to our knowledge of a homozygous patient.
A functional analysis was performed to assess CFTR protein
residual function: the patient was then referred to Verona CF
Regional Centre for a nasal potential difference (NPD) test.
NPD measurements were performed following the standardized
procedure [8] consistent with the recommendations provided by
the multicenter basic protocol [9]. In particular, PD was
determined by measuring the PD between a Ringers-filled
exploring catheter on the nasal mucosa and a reference bridge
(21-gauge needle filled with Ringers solution) inserted into the
forearm subcutaneous space.
Each nostril was examined using an otoscope; the inferior
turbinate was explored for the site of the most negative voltage
using a catheter (PE50 tubing, Fisher Scientific BD) connected
to an electrode. Baseline PD was perfused with Ringers and
subsequently the responses perfused to amiloride (1×10^–
4 M), chloride-free, isoproterenol (1×10^–5 M) and ATP
(1×10^–4 M) were sequentially acquired for a minimum of
3 min/each obtaining a period of stable signal for at least 30 s.
We perfused the solutions at 37 °C to obtain a larger activated
chloride conductance [10].
PowerLab (ADInstruments) software was used to acquire
and analyse the data. The data acquisition system ML870
PowerLab 8/30 was used in connection with a voltmeter with an
impedance of 8 W (Iso Millivolt Meter, World Precision
Instruments, Sarasota (WPI), FL, USA).
We measured on the left nostril basal PD of 28.96 mV, on the
right 21.55 mV (Fig. 2). The amiloride response was 15.89 mV
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isoproterenol response −2.31 mVand −0.74 mVon the left and
right, respectively (Fig. 2). The results of the exponential
formula proposed by Wilschanski et al. [11] were 1.33 on the
left and 1.15 on the right, and our values were below 0.9 in non-
CF subjects and N0.9 in CF patients (sensitivity 93.1%,
specificity 94.4%). The results in our patient were therefore
consistent with CF. Following ATP exposure hyper-polarization
was induced as shown in Fig. 2.
4. Conclusion
Clinical, molecular and CFTR functional data of an Arab CF
boy homozygous for the splicing mutation 875+1G→A are
shown.
In order to clarify the functional properties of the homozygous
genotype and identify the severity of the mutation, we performed
a NPD study.
According to the consensus statement for CF diagnosis [12]
and the CF diagnostic algorithm [13], NPD may detect the
abnormal transport of sodium and chloride characteristic of CF
and assist in the diagnosis or exclusion of CF [14,15].
Abnormalities of the CFTR transepithelial function correlate
with the number and severity of CFTR gene mutations [16] and
we found that amiloride, Cl− free and isoproterenol responses
were all consistently affected with CF diagnosis.
Beyond diagnosis in individual patients, electrophysiological
tests could be complementary to highly sensitivity genetic
analysis and should be availablewhen raremutations are detected.
Functional analysis performed on our homozygous patient
showed how 875+1G→A mutation deeply affects the CFTR
function leading to a very small amount of protein production.
875+1G→A can be defined as a severe mutation, as suspected
in the first mutation report. This functional evaluation is very
important for rare mutations, in particular in homozygous
subjects, as in this case. What remains unclear is why in our
patient pancreatic function did not seem to be affected.
Our patient's history underlines the importance to increase
the knowledge on CFTR gene alterations and their functional
effect: homozygote patients for CFTR mutations must be
assessed for in vivo functional study to classify as yet
uncharacterised CFTR mutations.
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